» Articles » PMID: 38804098

Differences in the Proteome Within Extracellular Vesicles Between Premalignant and Malignant Plasma Cell Disorders

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2024 May 28
PMID 38804098
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma-derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology of MM.

Methods: This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet-poor peripheral blood plasma of MGUS (n = 9) and MM (n = 12) patients using the size exclusion chromatography-based method and evaluated their proteome using a label-free proteomics workflow.

Results: In total, 2055 proteins were identified in SEVs, while 2794 proteins were identified in LEVs. The transferrin receptor (or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher in the LEVs derived from MM patients than in MGUS patients.

Conclusions: This study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.

Citing Articles

Therapeutically Harnessing Tumor Cell-Derived Extracellular Vesicles for Multiple Myeloma: Recent Advances and Future Perspectives.

Xiao S, Chen L, Chen Z, Li Q Pharmaceutics. 2024; 16(11).

PMID: 39598562 PMC: 11597712. DOI: 10.3390/pharmaceutics16111439.

References
1.
Malle E, Sodin-Semrl S, Kovacevic A . Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2008; 66(1):9-26. PMC: 4864400. DOI: 10.1007/s00018-008-8321-x. View

2.
Couch Y, Buzas E, Di Vizio D, Gho Y, Harrison P, Hill A . A brief history of nearly EV-erything - The rise and rise of extracellular vesicles. J Extracell Vesicles. 2021; 10(14):e12144. PMC: 8681215. DOI: 10.1002/jev2.12144. View

3.
Doyle L, Wang M . Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019; 8(7). PMC: 6678302. DOI: 10.3390/cells8070727. View

4.
Khalife J, Sanchez J, Pichiorri F . Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools. Diagnostics (Basel). 2020; 10(12). PMC: 7763630. DOI: 10.3390/diagnostics10121065. View

5.
Robinson M, Dasari S, Konopka A, Johnson M, Manjunatha S, Esponda R . Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans. Cell Metab. 2017; 25(3):581-592. PMC: 5423095. DOI: 10.1016/j.cmet.2017.02.009. View